Matinas biopharma holdings, inc. (MTNB)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Cash flows from operating activities:
Net loss

-18,367

-17,372

-15,426

-13,957

-14,023

-14,083

-14,084

-14,543

-15,100

-15,486

-13,750

-12,193

-9,850

-7,598

-7,713

-8,029

-8,809

-9,135

-10,173

-10,630

-10,652

-10,221

-8,978

-7,822

-5,740

-3,713

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

215

205

210

215

219

218

200

175

135

100

68

51

51

52

50

49

45

43

0

0

0

-

-

-

-

-

-

-

-

Change in deferred rent

-

-

-

-

-

-

-

190

174

157

97

0

1

2

2

10

10

9

0

0

0

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17

10

1

0

0

0

Stock based compensation expense

3,627

2,985

3,327

3,161

2,889

3,833

4,161

4,207

3,973

3,597

2,484

2,413

2,497

1,518

1,700

1,652

1,652

1,592

1,693

2,160

2,033

1,974

1,594

873

599

325

0

0

0

Amortization of operating lease right-of-use assets

459

452

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of finance lease right-of-use assets

109

122

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of shares in Matinas Holdings (July 11, 2013)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Common stock issued in lieu of bonus

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Issuance of equity instruments below fair value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Changes in operating assets and liabilities:
Grant receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-45

0

0

0

-

-

-

-

-

-

-

-

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

480

480

-206

-206

-100

-100

-3

-3

-40

0

0

0

0

-

-

0

0

Accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Operating lease liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Prepaid expenses and other current assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses

-

-

-

-

-

-

-464

-519

-884

-256

-0

-12

402

-189

-350

-47

44

111

204

44

41

29

101

15

13

84

0

0

0

Accounts payable

558

383

382

50

-78

-287

-38

44

-773

107

132

-22

626

-22

-72

-269

153

-73

-230

164

-76

-125

-48

197

186

336

0

0

0

Accrued expenses and other liabilities

160

842

704

335

548

97

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses - other liabilities

-

-

-

-

-

-

-

-

-

-

-112

78

-53

219

338

361

-172

-285

0

0

0

-

-

-

-

-

-

-

-

Net cash used in operating activities

-15,733

-14,092

-11,812

-10,376

-10,538

-10,321

-9,617

-9,764

-11,233

-11,459

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Purchase of marketable securities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sales of marketable securities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-7,034

-

-9,113

-8,565

-8,194

-7,961

-7,211

-6,488

-4,926

-2,987

0

0

0

Purchases of leasehold improvements and equipment

397

405

405

607

448

535

654

413

1,044

942

0

0

0

-

-

-

-

76

53

69

100

288

354

351

287

94

0

0

0

Acquisition of Aquarius - net of cash acquired

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-70

0

0

0

-

-

-

-

-

-

-

-

Net cash used in investing activities

-60,964

-6,011

-405

-607

-448

-535

-654

-413

-1,044

-942

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Net proceeds from public offering of common stock

46,554

30,103

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from common stock, issued for cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,000

10,000

8,522

4,282

0

0

0

0

-

-

-

0

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17

1

-29

-288

-354

-351

-287

-94

0

0

0

Return of membership capital in Matinas BioPharma LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Loans provided by founders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Repayment of loans provided by founders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

24

0

0

0

Proceeds from membership units issued for cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from redeemable convertible preferred stock issued for cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

500

0

0

0

Preferred stock issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

0

0

0

Common stock issuance cost

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

0

Proceeds from exercise of warrants

0

-

-

-

-

-

-

-

-

14,828

14,909

15,149

15,149

315

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of options

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments of capital lease liability - principal

81

81

84

81

71

59

44

30

22

17

0

0

0

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

Payments of note payable

-

199

319

399

362

370

377

383

387

330

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

47,263

29,851

38,200

38,862

46,030

15,867

7,847

7,758

705

15,602

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease)/increase in cash, cash equivalents and restricted cash

-29,435

9,748

25,982

27,877

35,043

5,009

-2,423

-2,419

-11,571

3,200

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from formation of holding's common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from formation warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from private placement warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

4,162

-

8,452

8,522

4,282

0

0

13,026

13,112

13,498

0

0

0

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

878

1,856

-6,027

-2,943

636

-644

-41

-3,941

-8,249

0

0

0

-

-

-

-

Net (decrease) increase in cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,416

0

0

0

Supplemental non-cash financing and investing activities:
Deferred offering costs included in accrued expenses and other liabilities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gains on marketable securities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred stock conversion into common stock - Series B

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cashless exercise of warrants

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred stock conversion into common stock - series A

-

-

-

-

-

133

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred stock conversion into common stock - series B

155

210

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unearned restricted stock grants

0

-

-

-

-

58

126

450

554

381

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets obtained in exchange for liabilities

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Capital lease for equipment purchase

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

111

0

0

0

-

-

-

-

Contingent equity consideration for Aquarius Merger

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Stock consideration for Aquarius merger

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,119

-2,119

-2,119

-2,119

0

0

0

0

-

-

-

-

Stock dividends issued

-

-

-

-

-

-

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred stock conversion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Additional paid-in-capital for modification of warrants

-

-

-

-

-

-

-

-

-

-

16,741

16,741

16,741

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Equipment acquired under capital lease

-

-

-

-

-

155

183

116

166

85

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of restricted stock for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0